

47. *Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62:7284-7290.*
48. *D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-4085.*
49. *Dziba J, Marcinek G, Venkataraman G, Robinson J, Ain K. Combretastatin A4 phosphate has primary antineoplastic activity against human/thyroid carcinoma cell lines and xenograft tumours. 74th Annual Meeting of the American Thyroid Association, Los Angeles, CA, 2002;p199.*
50. *Wang S, Lloyd RV, Hutzler M.J, Safran MS, Patwardhan NA, Khan A. The role of cell cycle regulatory protein, cyclin D1, in the progression of thyroid cancer. Mod Pathol 2000;13:882-887.*
51. *Erickson LA, Jin L, Wollan PC, Thompson GB, van Heerden J, Lloyd RV. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumours. Mod Pathol 1998;11:169-174.*
52. *Ringel MD, Hayre N, Saito J, et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 2001;61:6105-6111.*
53. *Bretz JD, Rymaszewski M, Arscott PL, et al. TRAIL death pathway expression and induction in thyroid follicular cells. J Biol Chem 1999;274: 23627-23632.*
54. *Ahmad M, Shi Y. TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention. Oncogene 2000;19:3363-3371.*
55. *Specht MC, Tucker ON, Hocever M, Gonzalez D, Teng L, Fahey III TJ. Cyclooxygenase-2 expression in thyroid nodules. J Clin Endocrinol Metab 2002;87:358-363.*
56. *Milena Braga-Basaria and Ringel MD. Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer: J Clin Endocrinol Metab 2003;88:1947-1960.*
57. *Zarnegar R, Brunaud L, Kanauchi H. et al. Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor: Surgery 2002;132:984-990.*

COMMENTS:

Differentiated thyroid cancer is a potentially curable disease in majority of cases. TSH control and activation of the sodium iodide symporter (NIS) remains the cornerstone of both adjuvant and salvage treatment. At the same time we also know that it is difficult to destroy all metastatic sites with radio-iodine to an acceptable level even in radioiodine concentrating or the differentiated variety. This has been assumed mainly due to low residence time of radioactive iodine in the thyroid cancer cells resulting in delivery of low radiation doses. Iodine as a base of common medications and its dietary intake are two important causes. Different strategies have been attempted to increase intracellular residency time of radioiodine. On the other hand majority of deaths due to thyroid cancer occurs due to its inability to concentrate radioiodine and de-differentiation of cancer cells is supposed to be the prime cause for this effect. It has been seen here that thyroid cancer, like many other malignancies is also characterized by genetic alterations resulting in

dysregulated cell growth and various attempts and strategies are being put forward for attempting re-differentiation of such thyroid cancer cells. This will be of prime importance in case some of these attempts are translated into actual clinical practice which could re-differentiate the cancer cells putting them under TSH regulation again so that it could further concentrate radioiodine. The aim of any alternative strategy thus should be two fold : firstly there should be an attempt to re-differentiate cancer cells and secondly to increase residence time of radioiodine in the cells. Gene therapy, especially for restoration of iodine uptake in thyroid cancers by re-expression of the NIS and re-differentiating properties of retinoic acid derivatives are the only ones that hold some promise in thyroid cancer. Some other agents which could be a potential adjuvant to increase the effectiveness of radioiodine, based on increasing NIS expression, are histone deacetylase inhibitors, suberoylanilide, hydroxamic acid and demethylating agents. These have been found to

increase radioiodine uptake. However opinion is divided regarding re-differentiating power of these derivatives and different groups have supported as well as rejected this approach. Two retinoid receptors, RAR α and RXR α have been identified which are differentially expressed in thyroid cancer cell lines and application of the amyloid precursor protein ligand generally suppress proliferation in those cell lines that expresses both these isoforms. However no difference in outcomes have been reported with any of these agents. All the same, the best curable cancer, is a treating physicians dilemma as soon as 'escape' phenomenon from radioiodine occurs in the form of de-differentiation in thyroid cancer cells when they no longer have the power of concentrating radioiodine. Most alternative strategies however still fall under the 'promising' category and do not have the potential to benefit clinical management

and improve outcome. Unfortunately not much benefit from chemotherapy or radiotherapy has been achieved in thyroid cancer except for some isolated reports in literature about the use of chemotherapeutic agents as a radio sensitizer for radioactive iodine. Recent reports point out that these de-differentiated thyroid cancer cells however retain the potential of glucose metabolism, thus facilitating their detection by positron emission tomography (PET) as ^{18}F FDG avid sites. Excision, if feasible, of some of these sites by radioguided surgery with a hand held PET detector may be a viable option in the future to deal with some of these situations.

Partha S. Choudhury

Department of Nuclear Medicine,
Rajiv Gandhi Cancer Institute & Research Center
Delhi-110085, India
E mail : pschoudhury@rgci.org

